Adalimumab is a fully human subcutaneously administered IgG anti-TNF antibody that binds to TNFα, preventing it from activating TNF receptors, thus downregulating the inflammatory reactions associated with several autoimmune diseases. The gene discussed is TNF; the disease is autoimmune disease.